Anixa Biosciences Inc
ANIX Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$2.99
KIRA · Stoqly’s AI analyst, in plain words
- Anixa Biosciences Inc lost $10.9M in fiscal 2025.
Market cap
$102M
P/E
—
Revenue
—
Net income
−$10.9M
Free cash flow
—
Operating margin
—
Anixa Biosciences Inc in 30 seconds · fiscal 2025
Does it make a profit?
−$10.9M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Anixa Biosciences Inc does
No business description yet.
- Fiscal year ends
- October 31, 2025
- Latest annual report
- 10-K · Jan 12, 2026
- Legal name
- Anixa Biosciences Inc
- CIK
- 0000715446
Anixa Biosciences Inc · ANIX
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $0.5M | — | $0.2M | $0.2M | — |
| Revenue growth | — | — | — | 0.0% | — |
| Operating margin | −2,565.6% | — | −5,243.3% | −6,586.2% | — |
| Net income | −$13.0M | −$13.6M | −$9.8M | −$12.6M | −$10.9M |
| Net margin | −2,530.1% | — | −4,671.9% | −5,978.1% | — |
| Diluted EPS | −$0.45 | $0.45 | −$0.32 | −$0.39 | −$0.34 |
| Cash | |||||
| Cash from operations | −$4.9M | −$6.5M | −$6.2M | −$7.3M | −$7.2M |
| Share buybacks | — | — | — | $0.0M | — |
| Share count change | 28.6% | −99.9% | 2.0% | 2.9% | 1.9% |
| Debt and strength | |||||
| Cash and short-term investments | $35.7M | $29.7M | $23.8M | $19.9M | $15.2M |
| Shareholders' equity | $35.4M | $29.0M | $24.3M | $20.0M | $15.2M |
| Current ratio | 28.3x | 14.8x | 12.5x | 8.5x | 8.1x |
| Returns and quality | |||||
| Return on equity | −58.6% | −42.2% | −36.8% | −56.6% | −62.2% |
| Return on tangible equity | −36.6% | −46.8% | −40.3% | −62.8% | −72.1% |
| Piotroski F-score | — | — | — | 2 | — |
| Altman Z'' | 10.4 | −6.6 | −14.2 | −27.2 | −42.8 |
Insiders bought, 12 months
$0.5M
4 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Anixa Biosciences Inc · ANIX
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $2.99 a share, the company is worth $102M.
Source: SEC EDGAR XBRL filings (CIK 0000715446). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.